https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-tibsovo-ivosidenib-patients-relapsed-or-refractory
FDA D.I.S.C.O. Burst Edition: FDA approval of Tibsovo (ivosidenib) for patients with relapsed or refractory myelodysplastic syndromes with a susceptible...
d is cfdaburstedition
https://www.cdc.gov/pcd/issues/2015/15_0191.htm
Preventing Chronic Disease (PCD) is a peer-reviewed electronic journal established by the National Center for Chronic Disease Prevention and Health Promotion....
communication strategiesusingdiverseengagerelapsed
https://www.sciencedaily.com/releases/2015/06/150629123433.htm
Researchers studying the pediatric cancer neuroblastoma have detailed how cancer-driving mutations evolve during chemotherapy, and they hope to exploit this...
in amutationsrelapsedchildrencancer
https://www.onclive.com/view/zanubrutinib-demonstrates-long-term-efficacy-safety-in-relapsed-refractory-cll-sll
Dec 7, 2025 - Zanubrutinib displayed long-term PFS and responses in patients with relapsed/refractory CLL/SLL.
long termzanubrutinibdemonstratesefficacysafety
https://www.kyprolis.com/about-multiple-myeloma
Understanding multiple myeloma can help you take an active role in treatment. Find more information about relapsed and/or refractory multiple myeloma.
what ismultiple myelomarelapsedrefractory
https://www.gilead.com/news/news-details/2019/kite-announces-end-of-phase-1-zuma-3-results-for-kte-x19-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia
Kite Announces End of Phase 1 ZUMA 3 Results for KTE X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
end ofresults forkiteannouncesphase
https://www.mcgill.ca/channels/event/visiting-speakers-program-oncology-dr-philippe-moreau-treatment-relapsedrefractory-multiple-myeloma-213081
Head Department of Hematology University Hospital of Nantes, France
visitingspeakersprogramoncologydr
https://www.sciencedaily.com/releases/2016/12/161206103448.htm
A research team has evaluated the use of hypomethylating agents in patients suffering from Acute Myeloid Leukemia (AML) who were resistant to treatment with...
alternativeoptionintensivechemotherapypatients
https://pubmed.ncbi.nlm.nih.gov/34470049/
Proteins in the antiapoptotic B-cell lymphoma 2 (BCL-2) family play a role in the pathophysiology of multiple myeloma (MM). Venetoclax is a highly selective,...
phasestudyvenetoclaxpluscarfilzomib
https://gamblingtherapy.org/mt/forum/topic/i-relapsed-again/
If you read my last post, you know that I am unemployed with no money coming in. Unfortunately, I relapsed again. I sold one of the last things I had that had...
relapsedgamblingtherapy
https://www.researchandmarkets.com/reports/5970091/relapsed-refractory-multiple-myeloma-market
The Relapsed Refractory Multiple Myeloma Market, valued at USD 21B in 2023, is projected to reach USD 34.4B by 2034, growing at a 4.6% CAGR.
multiple myelomarelapsedrefractorymarketepidemiology
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1374963/full
Acute myeloid leukemia (AML) is a severe hematological malignancy with poor outcomes, particularly in older adults. Traditional treatment options like high-d...
frontiersupdatesnovelimmunotherapeuticstrategies
https://www.cancer.gov/news-events/cancer-currents-blog/2021/blinatumomab-relapsed-b-cell-leukemia-children-young-adults
The immunotherapy drug blinatumomab (Blincyto) is more effective than chemotherapy in treating B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed in...
for childrenblinatumomabeffectiverelapsedleukemia
https://www.news-medical.net/news/20150812/AbbVies-venetoclax-Phase-2-trial-meets-primary-endpoint-in-patients-with-relapsedrefractory-CLL-with-17P-deletion.aspx
AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of...
primary endpointabbvievenetoclaxphasetrial
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1015081/full
Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) has poor clinical outcomes when treated with conventional salvage chemotherapy. Monotherapy ...
frontierszanubrutinibplussalvagechemotherapy